(Q57389418)

Dimitrinka Nikolova

14

0 references

Janus C Jakobsen

Janus C Jakobsen

1

0 references

Christian Gluud

Christian Gluud

16

0 references

Goran Hauser

Goran Hauser

6

0 references

Jian Ping Liu

13

Jian Ping Liu

0 references

author name string

Emil Eik Nielsen

2

0 references

Joshua Feinberg

3

0 references

Kiran Kumar Katakam

4

0 references

Kristina Fobian

5

0 references

Snezana Djurisic

8

0 references

Karl Heinz Weiss

9

0 references

Milica Bjelakovic

10

0 references

Goran Bjelakovic

11

0 references

Sarah Louise Klingenberg

12

0 references

Ronald L Koretz

15

0 references

Janus C Jakobsen

1

0 references

Goran Hauser

6

0 references

Goran Poropat

7

0 references

Dimitrinka Nikolova

14

0 references

Christian Gluud

Cochrane Database of Systematic Reviews

16

0 references

language of work or name

English

0 references

publication date

18 September 2017

0 references

published in

0 references

volume

9

0 references

page(s)

CD012143

0 references

cites work

Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Evaluation of VCH-759 monotherapy in hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUES

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

A glimpse at the future of hepatitis C therapy: the INFORM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-in

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Impact of Simeprevir Versus Telaprevir Triple Therapy for Chronic Hcv Infection on Patient-Reported Outcomes in Prior Non-Responders to Peginterferon/Ribavirin Results from the Phase Iii Attain Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Boceprevir for previously treated chronic hepatitis C virus genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Projected Clinical And Economic Impact Of Grazoprevir (Gzr, Mk-5172)/Elbasvir (Ebr, Mk-8742) For Chronic Hcv Genotype 1 Infection In Chronic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Weight loss during telaprevir-based triple therapy due to telaprevir-induced appetite loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Ribavirin monotherapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Ribavirin plus interferon versus interferon for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

SPIRIT 2013 statement: defining standard protocol items for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Virology and cell biology of the hepatitis C virus life cycle: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

New era for management of chronic hepatitis C virus using direct antiviral agents: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

New treatment strategies for hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Global epidemiology and genotype distribution of the hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines: 2. Framing the question and deciding on important outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines: 5. Rating the quality of evidence--publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines 6. Rating the quality of evidence—imprecision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines: 7. Rating the quality of evidence--inconsistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines: 8. Rating the quality of evidence--indirectness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines: 9. Rating up the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Direct-acting antivirals for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Industry sponsorship and research outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Treating viral hepatitis C: efficacy, side effects, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Global distribution and prevalence of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

When does mother to child transmission of hepatitis C virus occur?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Impact of new treatment options for hepatitis C virus infection in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

EASL Recommendations on Treatment of Hepatitis C 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143.PUB3

[APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection]

21 January 2018

1 reference

12 December 2020

Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment

1 reference

12 December 2020

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

12 December 2020

Boceprevir (Victrelis) for HCV: V is for victory and very complex

1 reference

12 December 2020

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients

1 reference

12 December 2020

Biomarkers and surrogate endpoints in clinical trials

1 reference

12 December 2020

Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.

1 reference

12 December 2020

Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial

1 reference

12 December 2020

A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV.

1 reference

12 December 2020

Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1

1 reference

12 December 2020

Is widespread screening for hepatitis C justified?

1 reference

12 December 2020

Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits

1 reference

12 December 2020

Hepatitis C: a changing epidemic

1 reference

12 December 2020

Sofosbuvir-ribavirin duo for chronic hepatitis C.

1 reference

12 December 2020

Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.

1 reference

12 December 2020

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Dac

1 reference

12 December 2020

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

1 reference

12 December 2020

Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents

1 reference

12 December 2020

Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?

1 reference

12 December 2020

Direct-acting antivirals for chronic hepatitis C.

1 reference

12 December 2020

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?

1 reference

12 December 2020

Surrogate end points in clinical trials: are we being misled?

1 reference

12 December 2020

Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention

1 reference

12 December 2020